Literature DB >> 3505192

Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3.

H Orimo1, M Shiraki, T Hayashi, T Nakamura.   

Abstract

To examine whether the administration of 1 alpha (OH)-vitamin D3 (1 alpha (OH)D3) could prevent the occurrence of vertebral crush fractures in senile osteoporosis, crush fractures of the thoracic or lumbar spine in senile osteoporosis treated with 1 alpha (OH)D3, 1.0 microgram/day (22 cases), 1 alpha (OH)D3 1.0 microgram/day + Ca 1.0 g/day (16 cases) or Ca 1.0 g/day (23 cases) were compared with those in non-treated controls (25 cases). The average treatment periods were 1.7 +/- 0.7 years in the 1 alpha (OH)D3 group, 2.1 +/- 1.0 years in the 1 alpha (OH)D3 + Ca group and 1.7 +/- 0.9 years in the Ca group. Occurrence of spinal crush fractures per 1000 patient years was significantly less in the 1 alpha (OH)D3 + Ca group (P less than 0.01) than in the non-treated control group. These findings suggest that administration of 1 alpha (OH)D3 is effective in preventing the occurrence of pathological fractures in senile osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3505192

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  21 in total

1.  A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation.

Authors:  Nirupama K Shevde; Lori A Plum; Margaret Clagett-Dame; Hironori Yamamoto; J Wesley Pike; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

2.  Prevention of post-menopausal bone loss with 1 alpha-hydroxy vitamin D3. A three-year prospective study.

Authors:  J M Pouilles; F Tremollieres; C Ribot
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

3.  Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes.

Authors:  M L Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2010-09

4.  Influence of age and body mass on the effects of vitamin D on hip fracture risk.

Authors:  J Ranstam; J A Kanis
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

5.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

Authors:  J A Kanis
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

6.  Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease.

Authors:  Y Sato; S Manabe; H Kuno; K Oizumi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

7.  Treatment of osteoporosis with vitamin D.

Authors:  J A Kanis; E V McCloskey; D de Takats; J Bernard; D M Zhang
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 8.  Calcium supplementation of the diet--II.

Authors:  J A Kanis; R Passmore
Journal:  BMJ       Date:  1989-01-28

Review 9.  Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview.

Authors:  J M Kaufman
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

Review 10.  Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.

Authors:  G Jones; D B Hogan; E Yendt; D A Hanley
Journal:  CMAJ       Date:  1996-10-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.